Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML

The multikinase inhibitor sorafenib improves event-free survival (EFS) when used with 7 + 3 in adults with newly-diagnosed acute myeloid leukemia (AML), irrespective of the FLT3-mutation status. Here, we evaluated adding sorafenib to cladribine, high-dose cytarabine, granulocyte colony–stimulating f...

Descripción completa

Detalles Bibliográficos
Autores principales: Halpern, Anna B., Rodríguez-Arbolí, Eduardo, Othus, Megan, Garcia, Kelsey-Leigh A., Percival, Mary-Elizabeth M., Cassaday, Ryan D., Oehler, Vivian G., Becker, Pamela S., Appelbaum, Jacob S., Abkowitz, Janis L., Orozco, Johnnie J., Keel, Siobán B., Hendrie, Paul C., Scott, Bart L., Ghiuzeli, M. Cristina, Estey, Elihu H., Walter, Roland B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463192/
https://www.ncbi.nlm.nih.gov/pubmed/37339483
http://dx.doi.org/10.1182/bloodadvances.2023010392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463192/
https://www.ncbi.nlm.nih.gov/pubmed/37339483
http://dx.doi.org/10.1182/bloodadvances.2023010392

Ejemplares similares